Abstract
Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid tumors like gynecologic tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease.
Highlights
Gynecologic malignancies are serious threats to women’s health worldwide
This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease
Patients received lentiviral transduced CART-meso cells with different doses: two were infused with (1~3)×108/m2 cells, and three were infused with (1~3)×107/m2 cells, both groups were evaluated as stable disease (SD) for 28 days
Summary
Gynecologic malignancies are serious threats to women’s health worldwide. traditional procedures like surgery, radiotherapy and chemotherapy have effectively decreased mortality, researchers are seeking new ideas and strategies to reduce the recurrence and metastasis of tumors, alleviate adverse drug reactions, as well as further improve the life quality of patients. Based on multiple triedand-true basic experiments, clinical trials later showed prominent advantages of this kind of engineered T cells named chimeric antigen receptor T cells (CAR-Ts) in patients with hematological malignancies [2,3,4,5]. Promoted by these significant achievements, adoptive T cell therapy has proved to be the potential adjuvant therapy for tumor treatment. Pioneer clinical application of engineered T cells, critical clinical trials carried out for gynecologic cancers and commercial CAR-T agents and related synergist approved by the FDA are included [10,11,12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
